SEARCH

SEARCH BY CITATION

References

  • Aisenberg, A.C. (1991) Malignant Lymphoma.. Lea & Febiger, Philadelphia and London, p. 14.
  • Barak, Y., Juven, T., Haffner, R. & Oren, M. (1993) MDM2 expression is induced by wild type p53 activity. EMBO Journal, 12, 461468.
  • Bates, S. & Vousden, K.H. (1996) p53 in signaling checkpoint arrest or apoptosis. Current Opinion in Genetics and Development, 6, 1218.
  • Blagosklonny, M.V. (1997) Loss of function and p53 protein stabilization. Oncogene, 15, 18891893.
  • Chen, W.-G., Chen, Y.-Y., Kamel, O.W., Koo, C.H. & Weiss, L.M. (1996) p53 mutations in Hodgkin's disease. Laboratory Investigation, 75, 519527.
  • Chilosi, M., Doglioni, C., Menestrina, F., Montagna, L., Rigo, A., Lestani, M., Barbareschi, M., Scarpa, A., Mariuzzi, G.M. & Pizzolo, G. (1994) Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood, 84, 42954300.
  • Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M.R., Pollack, D., Woodruff, J.M., Marechal, V., Chen, J., Brennan, M.F. & Levine, A.J. (1994) Molecular abnormalities of MDM2 and p53 genes in adult soft tissue sarcomas. Cancer Research, 54, 794799.
  • Daus, H., Trümper, L., Roth, J., Bonin, V.F., Möller, P., Gause, A. & Pfreundschuh, M.G. (1995) Hodgkin and Reed–Sternberg cells do not carry T-cell receptor γ gene rearrangements. Evidence from single-cell polymerase chain reaction examination. Blood, 85, 15901595.
  • Delabie, J., Shipman, R., Brüggen, J., DeStrooper, B., Van Leuven, F., Tarcsay, L., Cerletti, N., Odink, K., Diehl, V., Bilbe, G. & DeWolf-Peeters, C. (1992) Expression of the novel intermediate filament-associated protein restin in Hodgkin's disease and anaplastic large-cell lymphoma. Blood, 80, 28912896.
  • Dobbelstein, M., Wienzek, S., Konig, C. & Roth, J. (1999) Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene, 18, 21012106.
  • Doglioni, C., Pelosio, P., Mombello, A., Scarpa, A. & Chilosi, M. (1991) Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematology and Pathology, 5, 67.
  • Elenitoba-Johnson, K.S., Medeiros, L.J., Khorsand, J. & King, T.C. (1996) p53 expression in Reed–Sternberg Cells does not correlate with gene mutations in Hodgkin's disease. American Journal of Clinical Pathology, 106, 728738.
  • Engert, A., Burrows, F., Jung, W., Tazzari, P.L., Stein, H., Pfreundschuh, M.G. & Diehl, V. (1990) Evaluation of ricin-A-chain-containing immunotoxins directed against the CD 30 antigen as potential reagent for the treatment of Hodgkin's disease. Cancer Research, 50, 8488.
  • Gupta, R.K., Norton, A.J., Thompson, I.W., Lister, T.A. & Bodmer, J.G. (1992) p53 expression in Reed–Sternberg cells of Hodgkin's disease. British Journal of Cancer, 66, 649652.
  • Gupta, R.K., Patel, K., Bodmer, W.F. & Bodmer, J.G. (1993) Mutation of p53 in primary biopsy material and cell lines from Hodgkin's disease. Proceedings of the National Academy of Sciences of the United States of America, 90, 28172821.
  • Haupt, Y., Maya, R., Kazaz, A. & Oren, M. (1997) Mdm2 promotes the rapid degradation of p53. Nature, 387, 296299.
  • Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. (1991) p53 mutations in human cancers. Science, 253, 4953.
  • Joos, S., Otano-Joos, M., Ziegler, S., Brüderlein, S., Du Manoir, S., Bentz, M., Möller, P. & Lichter, P. (1996) Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood, 87, 15711578.
  • Joos, S., Küpper, M., Ohl, S., Bonin, V.F., Mechtersheimer, G., Bentz, M., Marynen, P., Möller, P., Pfreundschuh, M.G., Trümper, L. & Lichter, P. (2000) Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Research, 60, 549552.
  • Keleti, J., Quezado, M.M., Abaza, M.M., Raffeld, M. & Tsokos, M. (1996) The mdm2 oncoprotein is overexpressed in Rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. American Journal of Pathology, 149, 143150.
  • Kubbutat, M.H.G., Jones, S.N. & Vousden, K.H. (1998a) Regulation of p53 stability by Mdm2. Nature, 387, 299303.
  • Kubbutat, M.H., Ludwig, R.L., Ashcroft, M. & Vousden, K.H. (1998b) Regulation of Mdm2-directed degradation by the C terminus of p53. Molecular and Cellular Biology, 18, 56905698.
  • Kubbutat, M.H., Ludwig, R.L., Levine, A.J. & Vousden, K.H. (1999) Analysis of the degradation function of Mdm2. Cell Growth and Differentiation, 10, 8792.
  • Küpper, M., Loftin, U., Von Bonin, F., Gause, A., Pfreundschuh, M.G., Daus, H. & Trümper, L. (1996) Single cell PCR for the analysis of Hodgkin's disease: four years later. Annals of Oncology, 7, S35S39.
  • Lane, D.P. & Hall, P.A. (1997) MDM2 – arbiter of p53′s destruction. Trends in Biochemical Science, 22, 372374.
  • Leach, F.S., Tokino, T., Meltzer, P.S., Burell, M., Oliner, J.D., Smith, S., Hill, D.E., Sidransky, D., Kinzler, K.W. & Vogelstein, B. (1993) p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Research, 53, 22312234.
  • Lehmann, E.L. (1975) Blocked comparison for two treatments. Nonparametrics, Statistical Methods Based on Ranks (ed. by E.L.Lehmann), pp. 125155. McGraw-Hill, Berkeley.
  • Lichter, P., Bentz, M. & Joos, S. (1995) Detection of chromosomal aberrations by means of molecular cytogenetics: painting of chromosomes and chromosomal subregions and comparative genomic hybridization. Methods in Enzymology, 254, 334359.
  • Linzer, D.I.H. & Levine, A.J. (1979) Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell, 17, 4352.
  • Momand, J., Zambetti, G.P., Olson, D.C., George, D. & Levine, A.J. (1992) The mdm2 Oncogene Product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 12371245.
  • Montesinos-Rongen, M., Roers, A., Küppers, R., Rajewsky, K. & Hansmann, M.L. (1999) Mutation of the p53 Gene is not a typical feature of Hodgkin and Reed–Sternberg Cells in Hodgkin's disease. Blood, 94, 17551760.
  • Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L. & Vogelstein, B. (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 358, 8083.
  • Prives, C. & Hall, P.A. (1999) The p53 pathway. Journal of Pathology, 187, 112126.
  • Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E.E. & Collins, V.P. (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Research, 53, 27362739.
  • Roth, J., Daus, H., Trümper, L., Gause, A., Salamon-Looijen, M. & Pfreundschuh, M.G. (1994) Detection of immunoglobulin heavy-chain gene rearrangement at the single-cell level in malignant lymphomas: no rearrangement is found in Hodgkin and Reed–Sternberg cells. International Journal of Cancer, 57, 799804.
  • Said, J.W., Barrera, R., Shintaku, I.P., Nakamura, H. & Koeffler, H.P. (1992) Immunohistochemical analysis of p53 expression in malignant lymphomas. American Journal of Pathology, 141, 13431348.
  • Sánchez-Beato, M., Piris, M.A., Martinez-Montero, J.C., García, J., Villuendas, R., García, F.J., Orradre, J.L. & Martínez, P. (1996) MDM2 and p21WAF/CIP1, wild type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. Journal of Pathology, 180, 5864.
  • Sigalas, I., Calvert, H.A., Anderson, J.J., Neal, D.E. & Lunec, J. (1996) Alternative spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Medicine, 2, 912917.
  • Telenius, H., Pelmear, A.H., Tunnacliffe, A., Carter, N.P., Behmel, A., Ferguson-Smith, M.A., Nordenskjöld, M. & Pfragner, R. (1992) Ponder BAJP: cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes, Chromosomes and Cancer, 4, 257263.
  • Trümper, L., Brady, G., Bagg, A., Gray, D., Loke, S.L., Griesser, H., Wagman, R., Braziel, R., Gascoyne, R.D., Vicini, ST., Iscove, N.N., Cossman, J. & Mak, T.W. (1993) Single-cell analysis of Hodgkin and Reed–Sternberg cells. Molecular heterogeneity of gene expression and p53 mutations. Blood, 81, 30973115.
  • Trümper, L., Daus, H., Merz, H., Bonin, V.F., Loftin, U., Möller, P., Feller, A.C. & Pfreundschuh, M.G. (1997) NPM/ALK. fusion mRNA expression in Hodgkin and Reed–Sternberg cells is rare but does occur: results from single-cell cDNA analysis. Annals of Oncology, 8, S83.
  • Weber-Matthiesen, K., Pressl, S., Schlegelberger, B. & Grote, W. (1993) Combined immunophenotyping and interphase cytogenetics on cryostat sections by the new FICTION method. Leukemia, 7, 646649.
  • Weber-Matthiesen, K., Deerberg, J., Poetsch, M., Grote, W. & Schlegelberger, B. (1995) Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed–Sternberg cells in 100% of analysed cases of Hodgkin's disease. Blood, 86, 14641468.
  • Wu, X., Bayle, H.J., Olson, D. & Levine, A.J. (1993) The p53-mdm2 autoregulatory feedback loop. Genes and Development, 7, 11261132.
  • Xerri, L., Parc, P., Bouabdallah, R., Camerlo, J. & Hassoun, J. (1995) PCR.-Mismatch analysis of p53 gene mutation in Hodgkin's disease. Journal of Pathology, 175, 189194.
  • Zhang, Y., Xiong, Y. & Yarbrough, W.G. (1998) ARF promotes MDM2 degradation and stabilizes p53. ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92, 725734.